Light Sciences Oncology raises $40 million financing

29 July 2008

Washington-based Light Sciences Oncology, Inc. (LSO), a privately held company developing Light Infusion Therapy (Litx) to treat cancer and other conditions has raised $40.1 million in a Series C round of financing. The company raised $97 million in its first two rounds of financing. Investor names were not disclosed.

LSO plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients with hepatocellular carcinoma and metastatic colorectal cancer, a planned Phase III trial in glioblastoma multiforme (brain cancer), and early stage clinical trials in benign prostatic hyperplasia (BPH).

"We are approaching exciting milestones in the development of Litx, including the completion of enrollment in our Phase III primary liver cancer trial," said Llew Keltner, MD, PhD, president and chief executive officer of Light Sciences Oncology. "The Series C funds combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner."

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Light Sciences Oncology raises $40 million financing 29 July 2008 Washington-based Light Sciences Oncology, Inc. (LSO), a privately held company developing Light Infusion Therapy (Litx) to treat cancer and other conditions has raised $40.1 million in a Series C round of financing. The company raised $97 million in its first two rounds of financing. Investor names were not disclosed. LSO plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients with hepatocellular carcinoma and metastatic colorectal cancer, a planned Phase III trial in glioblastoma multiforme (brain cancer), and early stage clinical trials in benign prostatic hyperplasia (BPH). "We are approaching exciting milestones in the development of Litx, including the completion of enrollment in our Phase III primary liver cancer trial," said Llew Keltner, MD, PhD, president and chief executive officer of Light Sciences Oncology. "The Series C funds combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner." Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.